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Abstract
Benzodiazepines facilitate the inhibitory actions of GABA by binding to γ-aminobutyric acid type A receptors (GABAARs),
GABA-gated chloride/bicarbonate channels, which are the key mediators of transmission at inhibitory synapses in the brain.
This activity underpins potent anxiolytic, anticonvulsant and hypnotic effects of benzodiazepines in patients. However,
extended benzodiazepine treatments lead to development of tolerance, a process which, despite its important therapeutic
implications, remains poorly characterised. Here we report that prolonged exposure to diazepam, the most widely used
benzodiazepine in clinic, leads to a gradual disruption of neuronal inhibitory GABAergic synapses. The loss of synapses and
the preceding, time- and dose-dependent decrease in surface levels of GABAARs, mediated by dynamin-dependent
internalisation, were blocked by Ro 15-1788, a competitive benzodiazepine antagonist, and bicuculline, a competitive
GABA antagonist, indicating that prolonged enhancement of GABAAR activity by diazepam is integral to the underlying
molecular mechanism. Characterisation of this mechanism has revealed a metabotropic-type signalling downstream of
GABAARs, involving mobilisation of Ca
2+ from the intracellular stores and activation of the Ca2+/calmodulin-dependent
phosphatase calcineurin, which, in turn, dephosphorylates GABAARs and promotes their endocytosis, leading to
disassembly of inhibitory synapses. Furthermore, functional coupling between GABAARs and Ca
2+ stores was sensitive to
phospholipase C (PLC) inhibition by U73122, and regulated by PLCδ, a PLC isoform found in direct association with
GABAARs. Thus, a PLCδ/Ca2+/calcineurin signalling cascade converts the initial enhancement of GABAARs by
benzodiazepines to a long-term downregulation of GABAergic synapses, this potentially underpinning the development of
pharmacological and behavioural tolerance to these widely prescribed drugs.
Introduction
Benzodiazepines are among the most widely prescribed
class of drugs worldwide. Due to their rapid anxiolytic,
sedative-hypnotic, anticonvulsant and muscle relaxant
effects, they are prescribed for various conditions, most
prominently anxiety, insomnia and epileptic seizures [1].
Among these disorders, anxiety, often coinciding with
depression, is one of the most common mental health pro-
blems in the world (World Health Organization), and is the
largest cause of sickness absence in the UK [2], with ~1 in 6
adults being chronically affected according to Mental
Health Foundation UK. Although benzodiazepines are very
effective initially, the major limitation to their long-term use
is the development of tolerance to their pharmacological
effects, as well as dependence, resulting in severe with-
drawal symptoms upon drug cessation [1, 3]. Nevertheless,
the estimated prevalence of long-term use among patients
prescribed with benzodiazepine ranges from 25 to 76%,
which is equivalent to 2–7.5% of the general population [4].
Although benzodiazepines have been prescribed for over 50
years, the molecular mechanisms leading to tolerance are
still poorly understood.
* Jasmina N. Jovanovic
j.jovanovic@ucl.ac.uk
1 UCL School of Pharmacy, University College London,
London WC1N 1AX, UK
2 Neuroscience, Physiology and Pharmacology, University College
London, WC1E 6BT, London, UK
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41380-018-0100-y) contains supplementary















In the nervous system, benzodiazepines bind exclusively
to the GABAARs, the main inhibitory receptors in the brain,
and allosterically enhance their responsiveness to GABA
[5–7]. GABAARs are GABA-gated chloride/bicarbonate
channels built up as hetero-pentamers from a pool of 16
different subunits classiﬁed as α(1–6), β(1–3), γ(1–3), δ, ε,
π and θ, the combination of which determines physiological
and pharmacological properties, as well as the tissue and
subcellular distribution of these receptors. Benzodiazepines
selectively bind to γ2 subunit-containing GABAARs, which
are speciﬁcally localised to GABAergic inhibitory synap-
ses, thereby enhancing the strength of synaptic inhibition in
the brain. In addition to the γ2 subunit, synaptic GABAARs
incorporate two α subunits (α1, α2, α3 or α5) and two β
subunits (β2 or β3), with the benzodiazepine binding site
residing at the interface between the γ2 subunit and one of
the α subunits [8]. In neurons, synaptic GABAARs are
clustered in the vicinity of presynaptic GABA-releasing
terminals, to maximise the efﬁcacy of transmission, but they
are also mobile and dynamic, being continuously trafﬁcked
between the cytoplasm and the plasma membrane and, once
at the cell surface, in and out of synapses [9].
Tolerance to speciﬁc benzodiazepines develops at dif-
fering rates and degrees in patients, with sedative and
hypnotic tolerance within days, and anticonvulsant and
anxiolytic tolerance within weeks, as these effects are
mediated by speciﬁc subtypes of synaptic GABAARs in the
brain [10, 11]. Diazepam, the most widely used anxiolytic
drug in the clinic, is associated with prominent side effects
such as sedation, ataxia and cognitive impairments, due to
its non-selective binding to and modulation of all synaptic
GABAAR subtypes [1]. Believed to be an adaptation to
chronic enhancement of GABAergic signalling, tolerance
has been correlated to the observed uncoupling between
benzodiazepines and GABA binding sites [12, 13], mod-
iﬁcations in GABAAR subunit expression [14, 15], or
changes in the level and/or signalling of other neuro-
transmitters [11]. Endocytosis of GABAARs has also been
implicated in long-term effects of benzodiazepines, how-
ever the signalling mechanisms that regulate this process,
and the effects on inhibitory synapse structure and function,
remain poorly characterised [11].
We demonstrate here that prolonged treatment of neu-
rones with diazepam leads to disruption of neuronal inhi-
bitory GABAergic synapses as a consequence of prominent
time- and dose-dependent downregulation of surface
GABAARs, mediated by dynamin-dependent internalisa-
tion. In this process, prolonged activity of GABAARs trig-
gers a metabotropic signalling pathway which involves
mobilisation of intracellular Ca2+ and calcineurin-
dependent dephosphorylation and endocytosis of
GABAARs. This, in turn, is dependent on the activity of
phospholipase C (PLC), and mediated, at least in part, by
diazepam-modulated direct binding of PLCδ to GABAARs.
Thus, a metabotropic PLCδ/Ca2+/calcineurin signalling
cascade, activated by diazepam downstream of GABAARs,
leads to a long-term downregulation of GABAARs in
synapses in a negative feedback fashion, a process likely to
underpin the cellular correlates of pharmacological toler-
ance to these drugs. As such, it provides us with a new
repertoire of therapeutic drug targets that may pave the way




Sprague–Dawley rats (UCL-BSU) were housed and sacri-
ﬁced according to UK Home Ofﬁce guidelines, following
project approval by the UCL Ethics Committee. Primary
cultures of cerebrocortical neurones were prepared as
described previously [16]. Brieﬂy, cortical tissue was dis-
sected from embryonic day 16-17 (E16-17) rats, dissociated
by trituration in Ca2+ and Mg2+-free Hepes-buffered saline
solution (HBSS), and plated at the required density in
serum-free neurobasal medium, on either 0.1 mg/ml poly-D-
lysine-coated dishes or 0.1 mg/ml poly-L-lysine-coated
glass coverslips or glass bottom dishes. Cultures were
incubated in a humidiﬁed 37 °C/5% CO2 incubator (Her-
acell, Heareus, Germany), for up to 14 days prior to
experimentation.
Stable α1β2-HEK293 cell line was maintained under
selection with G418 disulphate (Neomycin; G5013-Sigma-
Aldrich) and Zeocin (R25001-Invitrogen) [17], while a
stable α1β2γ2-HEK293 cell line (Sanoﬁ-Synthelabo, Paris,
France) was maintained under selection with G418 dis-
ulphate [18].
Immunocytochemistry and synaptic cluster analysis
Cortical neurones (32,500/cm2 plated on glass coverslips)
were subjected to various treatments and processed for
immunolabelling using β2/3- and γ2-speciﬁc antibodies to
label the cell surface GABAARs, and, following permea-
bilization, VGAT and MAP2-speciﬁc antibodies, to label
GABAergic terminals and dendrites, respectively. Follow-
ing incubation with the corresponding Alexa-Fluor sec-
ondary antibodies (Supplementary Table S1), samples were
imaged using a laser scanning confocal microscope (Zeiss
LSM 710 Meta, Zeiss, Germany) with a ×63 oil-immersion
objective.
The size and number of GABAAR clusters, and their
colocalization with VGAT-terminals, were analysed using
Zen2.1 software, as previously described [19]. As the
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imaging was done in separate channels, a threshold for each
ﬂuorophore was determined by the formula (Threshold=
mean intensity+ (2 × standard deviation)). GABAAR clus-
ters were deﬁned as immuno-reactivity greater than 0.1 μm2,
with a mean ﬂuorescence value greater than 2 × standard
deviation of background ﬂuorescence, which were present
along the ﬁrst 20 µm length of MAP2-positive primary
dendrites. Colocalisation in separate channels (at least 50%
overlap) was determined by overlaying the images. Synaptic
elements size and numbers were analysed using Origin Pro
9.1 software, and the values were expressed as outlined in
the ﬁgure legends. Normality tests were performed using the
Shapiro–Wilk and Kolmogorov–Smirnov tests. After nor-
mality tests were performed on each of the groups, non-
parametric statistical analysis was done using
Mann–Whitney test with the conﬁdence interval of 95%, as
the groups showed non-Gaussian distribution.
GABAAR internalisation assay
Cell-surface receptors were labelled in living cultured neurons
or in α1β2-HEK293 cells transiently transfected with the
myc-γ2 cDNA, as described previously [19]. Brieﬂy, cover-
slips were incubated with ice-cold Buffer A (mM: 150 NaCl;
3 KCl; 2 MgCl2; 10 HEPES, pH 7.4; 5 Glucose), containing
0.35M sucrose for 5 min, followed by incubation with mouse
anti-β2/3 antibody (MAB341-MerckMillipore) for 30min at 4
°C in Buffer A containing 0.35M sucrose, 1 mM EGTA and
1% BSA. Cells were further incubated at 37 °C in Buffer A
containing 1mM CaCl2 and 5 µg/ml leupeptin, in the absence
or presence of diazepam (1 µM, Tocris), for 1 h to allow
internalisation of the labelled β2/3 subunit-containing
GABAARs. Cells were ﬁxed with 4% paraformaldehyde/4%
sucrose/PBS (PFA/PBS) and processed for immunolabelling
with anti-mouse Alexa-555 antibodies overnight at 4 °C. Cells
were subsequently permeabilized and labelled with anti-
mouse Alexa-488 antibodies (Supplementary Table S1) for 1
h at room temperature. Samples were imaged using a Zeiss
LSM 710 confocal microscope as above.
Cell surface ELISA
Cortical neurons (14 DIV, 100,000 cells/cm2 in 24-well
plates) or α1β2-HEK293 cells (111,000 cells/cm2 in 24-
well plates) transiently transfected with the myc-γ2 cDNA
using nucleofection (Lonza, Switzerland), were subjected
to treatments with vehicle (DMSO) or diazepam (1 µM),
in the absence or presence of various reagents (Supple-
mentary Table S2). All the treatments were done in
duplicate. Cells were ﬁxed with PFA/PBS, and changes in
surface and total levels of GABAARs were detected using
cell surface ELISA with β2/3 (1 µg/ml)- or myc (1 µg/ml)-
speciﬁc mouse monoclonal primary antibody and HRP-
conjugated anti-mouse secondary antibody [16]. Values
were expressed as mean percentage of vehicle treated
control (set at 100%) ± s.e.m., with the number of inde-
pendent repeats of each experiment (n) indicated in the
ﬁgure legends. Statistical analysis was carried out using
ANOVA with Dunnett post-hoc analysis and data plotted
using OriginPro 9.1.
Electrophysiology
Whole-cell recordings were made from cortical neurons (14
DIV), which were treated with DMSO or diazepam for 72 h,
as described before above. Patch pipettes (resistance 8–10
MΩ) were pulled from borosilicate glass tubing and ﬁlled
with an internal solution containing (mM): 144 K-gluco-
nate, 3 MgCl2, 0.2 EGTA, 2 Na2-ATP, 0.2 Na2-GTP, 10
HEPES pH 7.2–7.4, 300 mOsm. Spontaneous activity of the
neurons was recorded in current clamp mode (SEC 05 L/H,
NPI electronics, Tamm, Germany), in the presence of TTX
(1 μM), D-AP5 (50 μM) and CNQX (20 μM, all from
Tocris). Synaptic potentials recorded were ampliﬁed, low-
pass ﬁltered at 2 kHz, and digitised at 5 kHz using a CED
1401 interface and data acquisition programme, Signal 4.04
(Cambridge Electronic Design, Cambridge, UK), and ana-
lysed ofﬂine using Signal. Single sweep amplitudes were
measured from the baseline to the peak of the IPSP, and
selected for analysis if greater than 0.05 mV [19]. Statistical
analysis was conducted using the Student’s t test and data
plotted using OriginPro 9.1.
Biochemical assays
GST pull-down assays were performed, as described pre-
viously [16] using either cortical cell lysates, GFP-PLCδ- or
GFP-PRIP-transfected HEK293 cell lysates, or in vitro
translated PLCδ (TNT Quick Coupled Transcription/
Translation kit, Promega). For coimmunoprecipitation
analysis, primary cortical neurons or α1β2γ2-HEK293 cells
transfected with GFP-PLCδ, GFP-PRIP1 or both cDNAs
using Calcium–phosphate procedure [20], were incubated in
the absence or presence of diazepam (1 µM), or in the
absence or presence of diazepam/isoguvacine, respectively,
for 2 h, and lysed under nondenaturing conditions. Cell
lysates were incubated with 10 μg of either nonspeciﬁc goat
IgG, or GABAAR α1-speciﬁc antibody [21], followed by
incubation with Protein G-Sepharose. Precipitated proteins
were resolved using SDS–PAGE and immunoblotting
conducted as described previously [16], using antibodies
described in Supplementary Table S3. Protein concentration
was determined using either Bradford or BCA assays
(ThermoFisher).
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Intracellular Ca2+ imaging
Cortical neurones (14 DIV; 20,000 cells/cm2 in 35 mm glass
bottom dishes) were incubated with 5 µM Fluo-4 AM/
0.0025% pluronic F-127 (ThermoFisher) for 30 min at 37 °
C in the Recording Buffer (in mM: 10 HEPES pH 7.35, 156
NaCl, 3 KCl, 1.25 KH2PO4, 10 D-glucose, 2 CaCl2) con-
taining CNQX (20 µM), TTX (0.5 µM) and D-AP5 (50 µM)
[22]. Intracellular Ca2+ was recorded using Zeiss LSM 880
confocal microscope at 37 °C using a ×40 oil-immersion
objective and recordings were analysed using Zen2.1
SP2 software (Zeiss, Germany). To quantitate changes in
ﬂuorescence intensity, the ‘Region of Interest’ tool was
used to monitor regions in the somas and dendrites. The
maximal ﬂuorescence values following diazepam applica-
tion were normalised to the average baseline control before
the addition of diazepam (Ft/F0), and analysed using
ANOVA followed by Bonferonni post hoc analysis in
OriginPro 9.1 software.
Fluorescent imaging of GFP-PHPLCδ and DsRed-PRIP1
α1β2γ2-HEK293 cells (20,000 cells/cm2 in 35 mm glass
bottom dish) were transfected with 0.2 μg GFP-PHPLCδ
[23] in the absence or presence of 0.2 μg DsRed-PRIP1
[24] cDNA using Effectene (Qiagen) and cultured for 24
h. The cells were then incubated with Calcein Blue AM/
0.0025% pluronic F-127 (ThermoFisher) for 30 min at 37
°C in HBS (in mM 10 HEPES pH7.4, 150 NaCl, 3 KCl,
2 MgCl2, 5 D-glucose, 2 CaCl2). Calcein Blue, GFP-
PHPLCδ, or DsRed-PRIP1 emission was collected at
360–450 nm, 500–560 nm or 570–600 nm, respectively.
Images (12-bit resolution) were acquired every 5 s before
and after the bath application of diazepam (1 μM) and
isoguvacine (5 μM) for total of 15 min using Zeiss LSM
880 confocal microscope at 37 °C using the ×40 oil-
immersion objective and analysed using Zen2.1
SP2 software (Zeiss, Germany). Alternatively, cells were
treated for 1 h with diazepam (1 μM) and isoguvacine (5
μM) in HBS (in mM: 10 HEPES pH7.4, 150 NaCl, 3 KCl,
2 MgCl2, 5 D-glucose, 2 CaCl2) and subsequently ﬁxed
with 4% PFA/4% sucrose (w/v). Cell surface GABAARs
were labelled with an anti-β2/3 antibody (BD17) and an
Alexa Fluor 555 antibody. GFP-PHPLCδ emission was
collected at 500–560 nm and Alexa Fluor 555 emission
was collected at 570–600 nm. To quantify changes in
ﬂuorescence, the ‘Proﬁle’ tool was used to produce
ﬂuorescence proﬁles for each ﬂuorophore. The ﬂuores-
cence at the membrane (Fm) and the ﬂuorescence in the
cytoplasm (Fc), measured before and after bath application
of diazepam/isoguvacine, were used to produce a ﬂuor-
escence ratio Fm/Fc which was analysed using Students t-
test in OriginPro9.1 software.
Statistical analysis
Statistical analyses were performed using OriginPro9.1
software. Each dataset was tested for normality using the
Shapiro–Wilk test. For non-parametric data sets, the
Kruskal–Walis test followed by Mann–Whitney test was
used and the results were presented using boxplots showing
the median, interquartile range, standard deviation and the
mean, as speciﬁed in the ﬁgure legends. For parametric data
sets, either the two-tailed Student’s t-test or ANOVA fol-
lowed by Bonferonni post hoc analysis was used and the
results were expressed as the mean ± standard error of the
mean. The exact sample size and the number of independent
experiments performed, description of the samples and sta-
tistical analyses done were also speciﬁed in the ﬁgure
legends. The number of timed-pregnant rats/litters was
minimised by utilising the same tissue in multiple experi-
ments, including biochemical, immunocytochemical, elec-
trophysiological and live cell imaging experiments. Values
were considered to be statistically signiﬁcant for
p < 0.05 (*).
Results
Diazepam causes a time-dependent disassembly of
GABAergic synapses
Binding of diazepam to a speciﬁc allosteric site harboured
by the GABAAR at the interface between α and γ subunits
leads to a rapid increase in channel gating [25, 26] and
results in cumulative enhancement of GABA-mediated
transmission at inhibitory synapses. However, under the
conditions of sustained stimulation of GABAARs by dia-
zepam (1 μM; concentration analogous to measured plasma
concentration of diazepam taken orally by patients [27])
over the time course of 72 h, inhibitory GABAergic
synapses underwent a gradual decline in structural integrity
due to a signiﬁcant reduction in the size (Fig. 1a, b; *p <
0.05) and number of dendritic postsynaptic GABAAR
clusters (Fig. 1a, c; *p < 0.05), as well as the number of
colocalised GABAergic presynaptic terminals (Fig. 1a, d;
*p < 0.05), as observed in triple immunolabelling experi-
ments with GABAAR-β2/3-, vesicular GABA transporter
(VGAT)- and microtubule-associated protein (MAP2)-spe-
ciﬁc antibodies and confocal imaging in primary cere-
brocortical neurones. The extrasynaptic GABAAR clusters
monitored at the same time, which were signiﬁcantly
smaller in size, but larger in number than synaptic clusters,
remained unaffected by diazepam (Supplementary Fig-
ure 1a and b). The total number of immunolabelled
GABAergic or glutamatergic neurones remained unchanged
(data not shown). Consistent with the observed structural
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changes in synapses was a prominent reduction in the fre-
quency and amplitude (Fig. 1e–g; *p < 0.05) of miniature
inhibitory postsynaptic potentials (mIPSPs), recorded in
whole-cell current clamp mode, in neurones treated with
diazepam for 72 h. When Ro 15-1788 (ﬂumazenil), a spe-
ciﬁc competitive antagonist at benzodiazepine binding site
on the GABAAR, was applied together with diazepam, the
decrease in size (Fig. 1h, i; *p < 0.05) and number (Fig. 1h,
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j; *p < 0.05) of postsynaptic γ2-GABAAR clusters and the
decrease in the number of colocalised GABAergic terminals
(Fig. 1h, k; *p < 0.05) were completely abolished, indicat-
ing that direct diazepam binding to GABAARs was neces-
sary for the observed loss of GABAergic synapses.
However, Ro 15-1788 alone caused a decrease in the
number of GABAergic terminals colocalised with the
postsynaptic GABAARs, suggesting that it may have addi-
tional presynaptic effects that remain to be elucidated.
Diazepam triggers internalisation of GABAAR
receptors by activating calcineurin
In correlation with diazepam-dependent changes in post-
synaptic GABAARs clusters observed in primary cere-
brocortical neurones, a signiﬁcant overall reduction in
GABAAR surface expression was detected using a
GABAAR β2/3-speciﬁc antibody in cell-surface ELISA
experiments (Fig. 2). However, a decrease in cell surface
levels was detected earlier than the observed disassembly of
GABAergic synapses, reaching statistical signiﬁcance
within 1 h, and steady level after 24 h, in the continuous
presence of diazepam (Fig. 2a, black line; *p < 0.05). In
parallel ELISAs, in which the total levels of GABAARs
were measured, a statistically signiﬁcant decrease was
detected after 72 h of continuous diazepam treatment
(Fig. 2a, grey line; *p < 0.05). The effects of diazepam were
not only time- but also dose-dependent, with the lowest
effective concentration of 1 μM (Fig. 2b; *p < 0.05). A
signiﬁcant reduction in surface GABAARs was also
observed in α1β2γ2myc-HEK293 cells treated with 1 μM
diazepam in the presence of 5 μM isoguvacine (Fig. 2c, *p
< 0.05). The observed decrease in surface GABAARs in
neurones was abolished in the presence of Ro 15-1788
(Fig. 2d; *p < 0.05), again conﬁrming that this process was
initiated by direct diazepam binding to GABAARs. More-
over, this decrease in surface GABAARs was also abolished
by picrotoxin, a GABAAR channel blocker, in neurones and
in α1β2γ2myc-HEK293 cells (Fig. 2e, f, respectively; *p <
0.05), and by bicuculline (Fig. 2g; *p < 0.05), a competitive
antagonist which blocked the binding of GABA to these
receptors in neurones. Thus, the observed reduction in
surface levels of GABAARs appears to be a consequence of
prolonged diazepam-dependent stimulation of their activity
evoked by endogenous GABA released from spontaneously
active GABAergic neurones in culture (Fig. 1e) or by iso-
guvacine in α1β2γ2myc-HEK293 cells.
A time- and dose-dependent decrease in cell surface
GABAARs was also observed in the continuous presence of
speciﬁc agonists of these receptors at higher concentrations,
muscimol (50 μM; Supplementary Figure 2; *p < 0.05) in
primary neurons, or isoguvacine (50 μM; Fig. 2c; *p < 0.05)
in α1β2γ2myc-HEK293 cells. Importantly, a statistically
signiﬁcant diazepam (1 μM)-dependent potentiation of
muscimol effect at lower doses (1 or 5 μM muscimol;
*p < 0.05), but not at higher doses (10 or 50 μM muscimol;
Supplementary Figure 2a; p > 0.05) was observed, sug-
gesting that, at higher agonist concentrations, GABAARs
may have reached the maximal level of stimulation in these
preparations. That GABAAR activation by muscimol was a
necessary trigger for their downregulation from the cell
surface was conﬁrmed in neurones in the presence of
bicuculline (Supplementary Figure 2c; *p < 0.05) or picro-
toxin (Supplementary Figure 2d; *p < 0.05).
Crucially, the diazepam-dependent decrease in GABAA
Rs surface levels in neurones was abolished in the presence
of dynamin-inhibitory peptide (Fig. 2h; *p < 0.05), a pep-
tide which is able to penetrate the plasma membrane and
inhibit the endocytolic machinery of the cell [28]. This
indicates that the underlying cause of reduction at the cell
surface was indeed dynamin-dependent endocytosis of
GABAARs rather than inhibition in protein synthesis
or reduced insertion into the plasma membrane.
Fig. 1 Diazepam causes a time-dependent breakdown of GABAergic
inhibitory synapses upon direct binding to GABAARs. a Immunola-
beling of postsynaptic GABAAR β2/3-containing clusters (red) and
VGAT-positive presynaptic GABAergic terminals (cyan) along
MAP2-positive primary dendrites (20 µm; blue) of cortical neurons in
the absence or presence of diazepam (D; 1 μM), and the corresponding
graphs showing a decrease over time in b size (median/line-IQRs;
mean/dot ± s.d. whiskers; Mann–Whitney test, *p < 0.05) and c
number (mean ± s.e.m.; ANOVA/Bonferonni post-hoc test; *p < 0.05)
of synaptic β2/3 clusters, and d number of GABAergic terminals (mean
± s.e.m.; ANOVA/Bonferonni post-hoc test; *p < 0.05) contacting n
= 59, n= 70, n= 53 control (DMSO)-treated primary dendrites and n
= 70, n= 67, n= 44 diazepam-treated primary dendrites for 24 h, 48
h, and 72 h, respectively. Total of n= 17, n= 18 and n= 15 control
and n= 17, n= 17 and n= 17 diazepam-treated neurons, respectively,
collected from two independent experiments, were analysed in each
group. e Representative traces of mIPSPs recorded in cortical neurons
after 72 h treatment with control (DMSO) or diazepam (D; 1 μM),
before and after application of isoguvacine (+ I, 50 μM), followed by
picrotoxin (+ Pic, 50 μM; scale refers to all conditions), and corre-
sponding bar graphs (mean ± s.d.; Student’s t-test: *p < 0.05) showing
a diazepam-dependent decrease in f frequency and g amplitude of
mIPSPs and the effects of isoguvacine (+ I, 50 μM; grey bars) from n
= 7 control & n= 7 diazepam-treated cells collected from n= 3
independent experiments. h Immunolabelling of γ2-containing clusters
(red) and VGAT-GABArgic terminals (cyan) along MAP2-positive
dendrites (20 µm; blue) following 72 h treatment with control
(DMSO), or diazepam (D; 1 μM), in the absence or presence of Ro 15-
1788 (Ro; 25 μM), and the corresponding graphs showing a decrease
in i size (median/line-IQRs; mean/dot ± s.d. whiskers; Mann–Whitney
test, *p < 0.05), and j number of synaptic γ2 clusters (mean ± s.e.m.;
ANOVA/Bonferonni post-hoc test; *p < 0.05), and k decrease in the
number of GABAergic terminals (mean ± s.e.m.; ANOVA/Bonferonni
post-hoc test; *p < 0.05) contacting n= 49 control-treated & n= 45, n
= 53, n= 48 diazepam-, diazepam/Ro- or Ro-treated dendrites for 72
h, respectively. The total of n= 15, n= 14, n= 13, n= 16 neurons,
respectively, collected from two independent experiments, were ana-
lysed in each group. Scale bars= 20 μm (a, h-upper row) and= 5 μm
(a, h-lower row)
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Dynamin-inhibitory peptide also blocked a reduction in
surface GABAARs caused by high doses of muscimol
(Supplementary Figure 2e; *p < 0.05). Consistent with this
was the loss of cell surface receptors (Fig. 2i, red) and a
concomitant intracellular accumulation of endocytosed
GABAARs (Fig. 2i, green) in the presence of diazepam (1
μM) or muscimol (50 μM; Supplementary Figure 2f), which
were monitored using immunolabelling with the β2/3
antibody and confocal imaging in neurones. A small
amount of internalised β2/3 subunits observed in neurones
treated with vehicle control was likely due to constitutive
internalisation of GABAARs [19]. Likewise, a reduction of
surface GABAARs (Supplementary Figure 3b; red), with a
concomitant intracellular accumulation of the
endocytosed receptors (Supplementary Figure 3b; green),
was also observed in α1β2γ2myc-HEK293 cells
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(Supplementary Figure 3a) treated with the submaximal
doses of isoguvacine (5 μM), and this was further poten-
tiated by the addition of diazepam (1 μM).
Dynamin-dependent endocytosis of GABAARs is known
to be regulated by the activity of protein kinases and
phosphatases which determine the state of phosphorylation
of speciﬁc residues in the β and γ subunits of these receptors
[29], such that dephosphorylation by protein phosphatase 1
or 2A [16], or calcineurin (Ca2+/calmodulin-dependent
phosphatase 2B [30]), respectively, promotes their inter-
nalisation. To establish which of these phosphatases are
involved in diazepam-triggered endocytosis of GABAARs,
treatments of cultured neurones were carried out in the
presence of either low (0.05 μM) or high (1 μM) doses of
okadaic acid, to inhibit PP2A or PP2A/PP1, respectively, or
in the presence of cyclosporine A (1 μM), to inhibit calci-
neurin, and surface GABAARs were monitored using cell
surface ELISA. Although inhibition of PP2A alone, or both
PP2A and PP1, had no effect (Fig. 2j), inhibition of calci-
neurin signiﬁcantly attenuated GABAAR endocytosis trig-
gered by diazepam in neurones (1 μM; Fig. 2k; *p < 0.05),
or diazepam/isoguvacine (1 μM/5 μM; Fig. 2l, *p < 0.05) in
α1β2γ2myc-HEK293 cells, suggesting that dephosphorylation
of the γ2 subunit by calcineurin is a necessary step in this
process. This was corroborated in immunoblotting experi-
ments with P-Ser327-γ2-speciﬁc antibody, in which
diazepam-dependent dephosphorylation of the γ2 subunit in
neurones was abolished by cyclosporine A (Fig. 2m; *p <
0.05), and further supported by cell surface ELISA
experiments in which mutated S327A γ2myc subunit [31]
was expressed in the α1β2-HEK293 cell line (Fig. 2n;
*p < 0.05).
The relationship between diazepam-dependent depho-
sphorylation and internalisation of GABAARs and sub-
sequent destabilisation of GABAergic synapses was further
investigated in experiments in which changes in synaptic
elements, the size and number of postsynaptic γ2-GABAAR
clusters and the number of colocalised presynaptic
GABAergic terminals, were quantitatively assessed fol-
lowing prolonged diazepam treatments (72 h) in the absence
or presence of cyclosporine A (Fig. 3a–d). The decrease in
size (Fig. 3a, b; *p < 0.05) and number of postsynaptic γ2-
GABAAR clusters (Fig. 3a, c; *p < 0.05), and in the number
of colocalised presynaptic, VGAT-terminals (Fig. 3a, d; *p
< 0.05) detected after 72 h treatment with diazepam, were
effectively abolished in the presence of cyclosporine A,
further supporting the central role of calcineurin in this
process. Moreover, cyclosporine A and diazepam, when
applied together, caused a signiﬁcant increase in the size of
GABAAR clusters in comparison with the control, diazepam
or cyclosporine A alone (Fig. 3a, b; *p < 0.05).
Furthermore, a functional link between prolonged
diazepam-dependent stimulation of GABAARs and dis-
assembly of GABAergic synapses, was assessed in
experiments in which structural elements of synapses were
analysed in the presence of bicuculline (Fig. 3e–h). Bicu-
culline signiﬁcantly attenuated the diazepam-dependent
decrease in size (Fig. 3e, f; *p < 0.05) and number of
postsynaptic γ2-GABAAR clusters (Fig. 3e, g; *p < 0.05),
and in the number of colocalised presynaptic VGAT-
terminals (Fig. 3e, h; *p < 0.05). Diazepam and bicuculline
added together also caused a signiﬁcant increase in the size
of GABAAR clusters in comparison with control, diazepam
or bicuculline treatments alone (Fig. 3e, f; *p < 0.05).
Collectively, these data evince a cascade of signalling
events triggered by prolonged stimulation of synaptic
GABAARs which, in turn, leads to a calcineurin-mediated
dephosphorylation and endocytosis of these receptors, and a
consequent disassembly of GABAergic synapses. As
GABAARs are GABA-gated chloride/bicarbonate channels
which are impermeable to Ca2+, while calcineurin activa-
tion requires an increase in cytoplasmic Ca2+, the question
arises as to the nature of the signalling molecules that link
the activities of these seemingly unrelated pathways.
Fig. 2 Time and dose-dependent internalisation of GABAARs in
response to diazepam requires calcineurin activity. a Diazepam (D; 1
μM)-dependent decrease in surface (black) and total (grey) levels of
GABAARs over time (n= 5), and b in surface levels only in the
presence of increasing doses for 2 h (n= 4) in cortical neurones. c
Decrease in surface GABAARs in response to low doses of iso-
guvacine (I; 5 μM) is potentiated by diazepam (D; 1 μM) in
α1/β2/γ2myc-HEK293 cell line (n= 6). d–g Diazepam (D; 1 μM)-
dependent decrease in surface GABAARs is inhibited by Ro 15-1788
(Ro; 25 μM; d; n= 7), picrotoxin (Pic; 50 μM; e; n= 5), or bicuculline
(Bic; 50 μM; g; n= 4) in cortical neurones, and f picrotoxin (Pic; 50
μM; n= 6) in α1/β2/γ2myc-HEK293 cell line. h Diazepam (D; 1 μM)-
dependent decrease in surface GABAARs is inhibited by dynamin-
inhibitory peptide (DynIP; 25 μM; n= 5) in cortical neurones fol-
lowing 2 h treatments. i Immunolabelling of internalised (green) and
surface (red) GABAARs following 2 h treatments with diazepam (D; 1
μM; n= 2; scale bar= 5 µm). j Diazepam (D; 1 μM)-dependent
reduction of surface GABAARs is unaffected by inhibition of PP2A or
PP1 with low (0.05 μM) or high (1 μM) dose of okadaic acid,
respectively (OA; n= 6), but k it is prevented by inhibition of calci-
neurin by cyclosporine A (CyA; 1 μM; n= 6). l Diazepam (D; 1 μM)
/isoguvacine (I; 5 μM)-dependent reduction in surface GABAARs in
α1/β2/γ2myc-HEK293 cell line is prevented by inhibition of calcineurin
with cyclosporine A (CyA; 1 μM; n= 3). m Diazepam treatments (D;
1 μM; 2 h) cause GABAAR γ2 subunit dephosphorylation at Ser327 in
cortical neurones and this is prevented by cyclosporine A (CyA; 1 μM;
n= 2). Immunoblotting was done using an anti-PSer327-γ2 or anti-γ2
primary antibody, followed by alkaline phosphatase-conjugated sec-
ondary antibody and a colour reaction. Quantiﬁcation was done using
ImageJ. n Diazepam (D; 1 μM)/isoguvacine (I; 5 μM)-dependent
reduction in surface GABAARs in α1/β2/γ2myc-HEK293 cells is abol-
ished by S327A mutation in the γ2 subunit. Changes in surface
GABAARs were measured by cell surface ELISA using β2/3-speciﬁc
antibody in cortical neurones or myc-antibody in α1/β2/γ2myc-HEK293
cells and presented in graphs as mean ± s.e.m., with n= number of
independent experiments. Statistical analysis was done using ANOVA
with Bonferonni post-hoc test; *p < 0.05
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Diazepam triggers Ca2+ release from thapsigargin-
sensitive intracellular stores by activating PLC
To investigate the functional link between GABAARs and
calcineurin, we monitored the intracellular Ca2+ signal
using the Ca2+-indicator Fluo-4 in primary neurones by live
cell imaging, which has revealed that application of diaze-
pam (1 μM) evokes a prolonged increase in intracellular Ca2
+in neuronal dendrites and cell bodies (Fig. 4a, d, e, h; *p <
0.05). Importantly, this increase was completely abolished
when diazepam was applied in the presence of Ro 15-1788
(Fig. 4b, d; *p < 0.05) or bicuculline (Fig. 4c, d; *p < 0.05).
Furthermore, the rise in intracellular Ca2+ was also abol-
ished when the sarco/endoplasmic Ca2+ stores were deple-
ted in the presence of thapsigargin, a non-competitive
inhibitor of Ca2+ ATPase [32], prior to the addition of
diazepam (Fig. 4f, h; *p < 0.05). These ﬁndings indicate a
critical role of the intracellular Ca2+ stores in this process
and are consistent with a metabotropic-type signalling
classically mediated by phospholipase C (PLC) [33]. To
characterise this process further, live imaging of Fluo-4
labelled neurones was carried out in the presence of a
general PLC inhibitor U73122 (10 µM), which effectively
abolished the increase in intracellular Ca2+ in response to
diazepam-dependent activation of GABAARs (Fig. 4g, h;
*p < 0.05). In agreement with this, diazepam-dependent
down-regulation of surface GABAARs in neurones and in
α1β2γ2myc-HEK293 cells was also attenuated by thapsi-
gargin (Fig. 4i, left and right, respectively; *p < 0.05) and
U73122 (Fig. 4j; left and right, respectively; *p < 0.05), but
not by extracellular chelation of Ca2+ in the presence of
EGTA (Fig. 4k; left and right, respectively; *p < 0.05).
To monitor the activation of PLC by diazepam/iso-
guvacine, an indirect method was employed in which GFP-
tagged PH domain of PLCδ (GFP-PHPLCδ [23]) was
expressed in α1β2γ2-HEK293 cell line [18]. In confocal live
cell imaging experiments, due to activation of endogenous
PLC and depletion of PIP2 in response to diazepam/iso-
guvacine, the GFP-PHPLCδ, initially predominantly plasma
membrane bound (Fm), showed partial translocation to the
cytoplasm (Fc) within 5 min (green traces; Fig. 5a), resulting
in a signiﬁcant decrease in Fm/Fc ratio in comparison with
controls (Fig. 5b; *p < 0.05). That this activation was long-
lasting was shown by ﬂuorescent imaging of GFP-PHPLCδ
in α1β2γ2-HEK293 cells (green traces; Fig. 5c), which were
ﬁxed after 1 h in continuous presence of diazepam/iso-
guvacine and immunolabelled with GABAAR-β2-speciﬁc
antibody at the cell surface (pink traces; Fig. 5c), thus
yielded not only a signiﬁcant decrease in Fm/Fc ratio
(Fig. 5d; *p < 0.05), but also a decrease in surface
GABAARs.
Collectively, these data indicate that sustained diazepam-
dependent activation of GABAARs in neurones, beyond its
ionotropic effects, also has a long-lasting metabotropic
effect mediated by a PLC/Ca2+/calcineurin signalling cas-
cade which facilitates receptor internalisation from the cell
surface.
Regulation of GABAAR interaction with PLCδ or
PRIP1 by diazepam
Diazepam/isogivacine-dependent activation of PLC and its
requirement in diazepam-dependent mobilisation of intra-
cellular Ca2+ suggests that GABAARs may be in association
with some of the 23 known isoforms of PLC [33], via an
interaction that might directly impinge on the activity of
these enzymes. To test this hypothesis, the PLCδ isoform
was initially investigated given its structural similarity to
PRIP1 (PLC-related but catalytically inactive protein 1
[34]), which has been previously shown to directly associate
with GABAARs [35]. Coimmunoprecipitation experiments
from control and diazepam-treated neurones demonstrated
that PLCδ binds to GABAARs in controls, but disassociates
from them when diazepam is applied (Fig. 6a), while
Fig. 3 Diazepam-dependent loss of GABAergic synapses is prevented
by inhibition of calcineurin or GABAAR activity. a Immunolabelling
of γ2-containing clusters (red) and VGAT-positive presynaptic
GABArgic terminals (cyan) along MAP2-positive dendrites (20 µm;
blue) following 72 h treatment with control (DMSO) or diazepam (D;
1 μM), in the absence or presence of cyclosporine A (CyA; 1 μM), and
corresponding graphs showing b size (median/line-IQRs; mean/dot ±
s.d. whiskers; Mann–Whitney test, *p < 0.05), and c number of
synaptic γ2 clusters (mean ± s.e.m.; ANOVA/Bonferonni post-hoc test;
*p < 0.05), from n= 71 control dendrites & n= 85, n= 64, n= 73
dendrites of diazepam-, diazepam/cyclosporine A and cyclosporine A-
treated cells, respectively, of a total of n= 19, n= 19, n= 18, n= 19
neurons in each group collected from two independent experiments. d
Decrease in number of GABAergic terminals (mean ± s.e.m.;
ANOVA/Bonferonni post-hoc test; *p < 0.05) contacting n= 71
control-treated & n= 85, n= 64, n= 73 diazepam-, diazepam/
cyclosporine A- or cyclosporine A-treated dendrites for 72 h, respec-
tively, from a total of n= 19, n= 19, n= 18, n= 19 neurons in each
group, collected from two independent experiments. e Immunolabel-
ling of γ2-containing clusters (red) and VGAT-positive presynaptic
GABArgic terminals (cyan) along MAP2-positive dendrites (20 µm;
blue) following 72 h treatment with control (DMSO) or diazepam (D;
1 μM), in the absence or presence of bicuculline (Bic; 50 μM), and
corresponding graphs showing f size (median/line-IQRs; mean/dot ± s.
d. whiskers; Mann–Whitney test, *p < 0.05), and g number of synaptic
γ2 clusters (mean ± s.e.m.; ANOVA/Bonferonni post-hoc test; *p <
0.05), from n= 60 control dendrites & n= 63, n= 61, n= 65 den-
drites of diazepam-, diazepam/bicuculline and bicuculline-treated
cells, respectively, of a total of n= 16, n= 19, n= 18, n= 20 neu-
rons in each group collected from two independent experiments. h
Decrease in number of GABAergic terminals (mean ± s.e.m.;
ANOVA/Bonferonni post-hoc test; *p < 0.05), contacting n= 60
control-treated & n= 63, n= 61, n= 65 diazepam-, diazepam/bicu-
culine- or bicuculline-treated dendrites for 72 h, respectively, from a
total of n= 16, n= 19, n= 18, n= 20 neurons in each group, col-
lected from two independent experiments. Scale bars= 20 μm (a, e-
upper row) and= 5 μm (a, h-lower row)
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PRIP1 shows the opposite translocation (Fig. 6b). To
investigate these interactions further, in vitro binding assays
were carried out in which puriﬁed GST-fusion proteins
incorporating the intracellular TM3-4 loop of different
GABAAR subunits were incubated with lysates of PLCδ-
GFP expressing HEK293 cells, revealing that PLCδ binds
to the β2 and β3 subunits of GABAARs speciﬁcally
(Fig. 5c). Using truncation mutants of the β3 subunit TM3-4
loop, two distinct binding regions, between 303–333 (Q1)
and 366–396 (Q3) residues, were identiﬁed (Fig. 5d) and, in
subsequent experiments, demonstrated to mediate the direct
binding of PLCδ (Fig. 5e). Interestingly, PRIP1-GFP was
also found to interact with the same Q1 and Q3 regions of
the GABAAR β3 subunit as PLCδ (Fig. 5f), suggesting that,
in situ, these two proteins may be in competition for their
binding to GABAARs. Based on the sequence similarity in
the Q1 and Q3 regions between the β2 and β3 subunits, a
potential binding sequence for both PLCδ and PRIP1 was
identiﬁed (FXXXGXQXXK; Fig. 5g).
Dissociation of PLCδ from GABAARs upon their acti-
vation by diazepam/isoguvacine and the concurrent increase
in PRIP1 binding were conﬁrmed by coimmunoprecipitation
Fig. 4 Diazepam triggers release of Ca2+ from the intracellular stores which is required for internalisation of GABAARs and prevented by Ro 15-
1788, bicuculline, thapsigargin and U-73122. Time lapse imaging of intracellular Ca2+ in Fluo-4-labelled cortical neurones treated with diazepam
(D; 1 μM) alone (a, inset: representative images before and after diazepam addition; scale bars= 20 μm), or in the presence of Ro15-1788 (Ro, 25
μM; b) or bicuculine (Bic, 50 μM; c), shown as a ﬂuorescence ratio Ft/F0, and d quantiﬁed at the peak of response to diazepam in dendrites and
somas (d; mean ± s.e.m.; ANOVA/Bonferonni post-hoc test; *p < 0.05; n= 5 neurones in each group from 2 independent experiments). e
Diazepam (D; 1 μM)-dependent increase in intracellular Ca2+ (insert: representative images before and after diazepam addition; scale bars= 20
μm) is inhibited by thapsigargin (T; 2 μM; f) and U-73122 (U; 10 μM; g). h Ft/F0 was quantiﬁed at the peak of response to diazepam in dendrites
and somas of labelled cortical neurons (mean ± s.e.m.; ANOVA/Bonferonni post-hoc test; *p < 0.05; n= 4 neurones in each group from 2
independent experiments). i–k Diazepam (D; 1 μM)-dependent internalisation of GABAARs in neurones (left), and Diazepam (D; 1 μM)/Iso-
guvacine (I; 5 μM)-dependent internalisation of GABAARs in α1/β2/γ2myc-HEK293 cells (right) are prevented by thapsigargin (T; 2 μM; i) and U-
73122 (U; 10 μM; j), but insensitive to EGTA (E; 1 mM; k). Changes in surface GABAARs were measured by cell surface ELISA using β2/3-
speciﬁc antibody in neurones or myc-antibody in α1/β2/γ2myc-HEK293 cells and presented in graphs as mean ± s.e.m. Statistical analysis was done
using ANOVA with Bonferonni post-hoc test; *p < 0.05 (n= 7 thapsigargin, n= 5 U-73122, n= 9 EGTA independent experiments)
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from lysates of α1β2γ2-HEK293 cells transfected with GFP-
PLCδ and GFP-PRIP1 cDNA (Fig. 5h), further supporting
the observation that the binding of these proteins is regulated
by the level of GABAAR activation, but in a mutually
exclusive manner.
Altogether, the data suggest that a switch in association
between GABAARs and catalytically-active PLCδ versus
catalytically inactive PRIP1, may be a critical regulatory
step in the signalling pathway that leads to diazepam-
dependent internalisation of GABAARs. To test this
hypothesis, the intracellular localisation of GFP-PHPLCδ and
dsRed-PRIP1 was monitored simultaneously by live cell
imaging in transfected α1β2γ2-HEK293 cells before and 5
min after the bath application of diazepam/isoguvacine
(Fig. 6i). GFP-PHPLCδ showed no apparent translocation
from the membrane to the cytoplasm (green traces, Fig. 6i)
and no change in Fm/Fc ratio (Fig. 6j, left) when dsRed-
PRIP1 was also expressed, suggesting that activation of
endogenous PLCδ in response to diazepam/isoguvacine was
blocked. In contrast, dsRed-PRIP1 showed further accu-
mulation in the plasma membrane (red traces, Fig. 6i)
resulting in an increase in Fm/Fc ratio (Fig. 6j, right).
Moreover, a decrease in surface GABAARs in response to
diazepam/isoguvacine in α1β2γ2myc-HEK293 cells detected
by cell surface ELISA, was completely abolished by over-
expression of PRIP1 (Fig. 5k), suggesting that PRIP1 may
serve as an inhibitor of this signalling pathway, thereby
preventing the process of GABAARs internalisation and
alleviating the consequent loss of inhibitory GABAergic
synapses (Fig. 5l).
Discussion
The prevalence of stress-related psychiatric disorders,
particularly anxiety mixed with depression, panic attacks
or insomnia, leads to an estimated 12 million prescrip-
tions of benzodiazepines every year in the UK (UK
Addiction Treatment Centres). However, our current
understanding of the long-term effects of benzodiaze-
pines on cellular and molecular processes in the brain
remains limited.
In this study we have revealed that prolonged exposure
of neurons to diazepam activates a novel Ca2+ signalling
cascade downstream of GABAARs, which in a negative
feedback fashion, leads to a gradual removal of these
Fig. 5 Diazepam/Isoguvacine-
dependent translocation of GFP-
PHPLCδ1 from the cell membrane
to the cytoplasm in α1/β2/γ2-
HEK293 cells. a Live imaging
of a Calcein blue-labelled cell
(inset) showing changes in GFP-
PHPLCδ1 ﬂuorescence intensity
proﬁle (green) prior to (left) and
5 min after the addition of
Diazepam (D; 1 μM)/
Isoguvacine (I; 5 μM) (right). b
Quantiﬁcation of ﬂuorescence F
(membrane)/F(cytoplasm) ratio
of GFP-PHPLCδ1 (green; mean ±
s.e.m.; Student t-test; *p < 0.05;
n= 10 cells from 2 independent
experiments). c Imaging of
surface GABAAR-β2-subunit in
ﬁxed HEK293 cells (red)
expressing GFP-PHPLCδ1 (green)
in control (DMSO, left) and
Diazepam (D; 1 μM)/
Isoguvacine (I; 5 μM) treated
samples for 1 h (right), showing
superimposed ﬂuorescence
intensity proﬁles across the
selected cells. d Quantiﬁcation
of ﬂuorescence F(membrane)/F
(cytoplasm) ratio of GFP-
PHPLCδ1 (green; mean ± s.e.m.;
Student t-test; *p < 0.05; n= 10
cells from 2 independent
experiments)
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receptors from the postsynaptic membrane and disassembly
of inhibitory synapses, thus rendering the system unre-
sponsive to any further diazepam treatments. Although
studied in vitro, these processes are closely correlated in
time to in vivo downregulation of GABAARs and the onset
of tolerance to benzodiazepines in rodents [36]. These
processes are however in sharp contrast with the initial
diazepam-dependent facilitation of GABAAR channel gat-
ing activity [25], increased mobilisation of GABAARs to
synapses [37, 38], and enhanced inhibitory synaptic trans-
mission [39], possibly representing a form of neuronal
adaptation in order to maintain a critical balance between
the excitation and inhibition in the brain.
Our experiments demonstrate that sustained activation of
GABAARs by diazepam, in the presence of ambient GABA
(Fig. 1e [39]), is a key trigger of this signalling cascade
which involves PLCδ activation, mobilisation of intracel-
lular Ca2+ and activation of calcineurin. A key role of
calcineurin in diazepam-dependent endocytosis of
GABAARs is in agreement with the previously reported
effects on GABAAR migration out of the synaptic contacts
[31, 40, 41], and internalisation from the cell surface [42].
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Subsequent loss of inhibitory synapses indicates that
depletion of postynaptic GABAARs destabilises synaptic
contacts, an observation consistent with their activity-
dependent regulation reported previously [43], and also
with a direct structural role of GABAARs in the formation
of these synapses [17, 44, 45]. As changes in cell surface
GABAARs are known to precede changes in the post-
synaptic gephyrin scaffold [46], our ﬁndings are also in
agreement with the previously observed diazepam-
dependent reduction in the size of gephyrin clusters [47].
At later time points of incubation with diazepam, an overall
reduction in GABAAR expression is likely to occur due to
induced proteolysis of internalised receptors, as previously
reported for the prolonged ﬂurazepam treatments [48], or
due to a decrease in the rate of transcription and/or trans-
lation of GABAAR subunits, as shown in vivo by mon-
itoring the mRNA levels [10, 11, 15, 49].
Another important step in this cascade is diazepam-
dependent rise in intracellular Ca2+ originating from the
thapsigargin-sensitive intracellular stores and mediated by
the activation of PLCδ, which is consistent with a
metabotropic-type signalling by GABAARs in mature
neurones operating in addition to their ‘canonical’ iono-
tropic signalling as chloride/bicarbonate channels. In
contrast to immature neurones, where GABAAR activa-
tion generally leads to depolarisation and inﬂux of Ca2+
through voltage-gated Ca2+ channels [50, 51], this sig-
nalling pathway is insensitive to the extracellular chela-
tion of Ca2+ with EGTA. Furthermore, the requirement
for PLC activity in this process is in agreement with the
biochemical evidence for a direct association between
GABAAR β subunits and PLCδ, which was also detected
in recent proteomic analyses of GABAAR binding pro-
teins [52, 53]. Although PLCδ may not be the only iso-
form of PLC able to interact with GABAARs, its extensive
structural similarity with PRIP1, a well characterised
GABAAR receptor interacting protein [54], is of sig-
niﬁcance. Interestingly, our experiments demonstrate that
PLCδ disassociates from GABAARs with diazepam
treatments, suggesting that this displacement may be
required for its activation, particularly if the PLCδ bind-
ing to GABAARs resembles its binding to calmodulin via
an auto-inhibitory region which renders it inactive [55].
Exactly how dissociation of PLCδ from GABAARs occurs
remains to be elucidated, although we hypothesise that
this could be caused by a conformational change in the
receptor upon activation, or by accumulation of nega-
tively charged chloride and depletion of bicarbonate,
possibly changing the pH or osmolality [56] in the vici-
nity of the receptor. At the same time, however, these
conditions facilitate the binding of PRIP1 to GABAARs,
which, together with identiﬁed common binding sites in
the β subunits, suggests that the two proteins may be in
competition with each other. The interplay between PLCδ
and PRIP1 in binding to GABAARs may represent an
important on/off switching mechanism regulating this
signalling pathway and downstream endocytosis of
GABAARs. This is because PRIP proteins are not only
catalytically inactive variants of PLCδ unable to generate
IP3 and DAG [34], but they also inhibit PLC signalling
due to high afﬁnity binding of IP3, thereby sequestering it
away from the IP3 receptor on the intracellular Ca
2+ stores
[57]. That overexpression of PRIP1 inhibited diazepam-
dependent activation of PLCδ and diazepam-dependent
down-regulation of surface GABAARs in heterologous
systems, suggests that this protein can act as an inhibitor
by outcompeting the PLCδ binding to GABAARs. In
neurones, PRIP1 is likely to be a temporary block of this
pathway, due to its removal together with GABAARs
undergoing endocytosis [58]. This is in agreement with
Fig. 6 Diazepam triggers dissociation of PLCδ from GABAARs in situ
leading to activation of PLCδ/Ca2+/calcineurin signalling pathway,
which is negatively regulated by PRIP1. a Immunoprecipitates of
GABAARs from control and diazepam (D; 1 μM)-treated cortical
neurones were probed with PLCδ- (n= 3) or b PRIP1- (n= 4) spe-
ciﬁc antibody. c–e PLCδ-GFP binds directly to the intracellular loop of
the GABAAR β2 and β3 subunits Q1 (303-366 aa) and Q3 (366-396 aa)
regions in GST pull-down assays (n= 3). f PRIP1-GFP binds directly
to the β3 subunit Q1 and Q3 loop regions in the GST pull-down assays
(n= 3). g Predicted PLCδ- and PRIP1- binding sites in the Q1 and Q3
regions of the β2 and β3 subunits. h Immunoprecipitates of GABAARs
from control (DMSO) or Isoguvacine (I; 5 μM)-, Diazepam (D; 1 μM)/
Isoguvacine (I; 5 μM)- or Isoguvacine (I; 50 μM)-treated α1β2γ2-
GABAAR HEK293 cells expressing both GFP-PLCδ and GFP-PRIP1
were probed with the GFP-speciﬁc antibody (n= 2). (i) Over-
expression of PRIP1 inhibits partial translocation of GFP-PHPLCδ1 in
response to Diazepam (D; 1 μM)/Isoguvacine (I; 5 μM) in α1β2γ2-
HEK293 cells. Live imaging of a Calcein blue-labelled cell (blue)
expressing GFP-PHPLCδ1 (green) and dsRed-PRIP1 (red; top panels)
and superimposed ﬂuorescence intensity proﬁles prior to (left) and 5
min after the addition of Diazepam (D; 1 μM)/Isoguvacine (I; 5 μM)
(right). j Quantiﬁcation of ﬂuorescence F(membrane)/F(cytoplasm)
ratio of GFP-PHPLCδ1 (green; left) and dsRed-PRIP1 (red; right), both
shown as mean ± s.e.m. (Student t-test; *p < 0.05; n= 10 cells from 2
independent experiments). k Overexpression of PRIP1 inhibits Dia-
zepam (D; 1 μM)/Isoguvacine (I; 5 μM)-dependent internalisation of
GABAARs. Changes in surface GABAARs were measured by cell
surface ELISA with anti-myc-speciﬁc antibody labelling the
γ2 subunit, and presented as mean ± s.e.m. (n= 4). Statistical analysis
was done using ANOVA with Bonferonni post-hoc test; *p < 0.05; n
= number of independent experiments. l Schematic diagram of the
GABAAR/PLCδ/Ca2+/calcineurin feed-back mechanism underlying
diazepam-dependent downregulation of GABAARs. According to this
model, sustained activation of synaptic GABAARs by diazepam trig-
gers a metabotropic, PLCδ/Ca2+/calcineurin signalling pathway which
leads to receptor dephosphorylation by calcineurin, initiation of
dynamin-dependent endocytosis resulting in a decrease in the size and
number of postsynaptic GABAAR clusters, and disassembly of inhi-
bitory synapses. This mechanism is ‘switched off’ when PRIP1,
PLCδ-related but catalytically inactive protein, outcompetes the PLCδ
in binding to GABAARs, thereby preventing the activation of PLCδ
and downstream Ca2+/calcineurin-dependent internalisation of these
receptors
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the effects of PRIP gene deletion in mice, which show
increased intracellular Ca2+ and calcineurin activity [57],
decreased levels of synaptic γ2-containing GABAARs
receptors, reduced sensitivity to diazepam and increased
anxiety-like behaviour [59]. We therefore hypothesise
that, when the ‘off’ switch (PRIP) is no longer present,
PLCδ recruitment to GABAARs allows continuous acti-
vation of this signalling pathway and depletion of
synaptic GABAA receptors, leading to their structural and
functional deﬁcits in inhibitory synapses. This diazepam-
induced breakdown of inhibitory GABAergic synapses
not only correlates well in time with the development of
tolerance but also provides a likely explanation for the
severe withdrawal symptoms, increased anxiety and even
seizures, observed in animal models and patients follow-
ing sudden termination of chronic benzodiazepine treat-
ment [60], possibly due to uncontrolled excitatory drive in
the absence of functional inhibition.
This signalling mechanism offers a new spectrum of pos-
sible molecular interventions that could be tailored towards
extending the initial highly beneﬁcial clinical outcomes of
benzodiazepines, while preventing the subsequent disruption
of GABAergic synapses and development of pharmacological
and behavioural tolerance to these widely prescribed drugs.
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